Skip to content

#细胞治疗

Today 1 items
TodayOct 16Fri
  1. biopharmadive.com49

    Belgian startup revives Galapagos CAR-T research

    Lakefront Biotherapeutics, formerly Galapagos, has sold its cell therapy programmes to Belgian startup Armed Cell Therapeutics for 8 million euros up front, with up to $230 million more in future payments. The deal covers two armed CAR-T therapies nearing human testing in non-Hodkin lymphoma and small cell lung cancer, plus three undisclosed preclinical projects. Armed Cell named Willemijn Kremer, a former Galapagos cell therapy executive, as CEO, replacing interim CEO Paul Stoffels.

    Why it matters: Revives shelved CAR-T programmes under a new company after Galapagos wound down its cell therapy research.

Oct 15Thu
  1. biospace.com49

    Stoffels strikes up new biotech in return to Galapagos cell therapy mission

    Former Galapagos CEO Paul Stoffels has founded Armed Cell Therapeutics in Belgium to acquire the CAR T cell therapy programs that Galapagos, now Lakefront Biotherapeutics, abandoned in October 2025. Armed pays about $9 million upfront plus $230 million in milestones and royalties, just under $240 million in total, for the preclinical assets, which originated from AboundBio and target non-Hodgkin lymphoma and small cell lung cancer. Stoffels will chair the board, Willemien Kremer becomes CEO, and the company aims to move the programs into the clinic.

Oct 14Wed
  1. biocentury.com46

    Duracyte: Turning the patient into the bioreactor

    Duracyte, a Rice University spinout based in Houston, is developing subcutaneous implants of engineered human cells that continuously secrete biologics in the body for up to a year, with the aim of replacing repeated infusions and injections. The work has drawn roughly $120 million in non-dilutive funding. The company plans to start its first clinical trial in the first half of next year, testing an implant that produces the checkpoint inhibitor ipilimumab in patients with peritoneal cancer.

Oct 13Tue
  1. biopharmadive.com47

    Parkinson’s cell therapy developer files to go public

    Aspen Neuroscience, founded in 2018, has filed registration documents to list on the Nasdaq under ticker "ASPE" and would be the first Parkinson's-focused cell therapy developer to go public in the U.S. Its lead therapy sasineprocel, or ANPD001, reprograms a patient's own cells into dopamine-producing neurons and is entering late-stage testing after an early-stage trial. Aspen has raised about $347 million, posted a $62 million net loss in 2025 and nearly $37 million in the first six months of this year, and warned of substantial doubt about its ability to continue as a going concern without substantial additional capital.

Oct 9Fri
  1. biopharmadive.com52

    In the hunt for reverse merger targets, Caribou could be prized game

    Caribou Biosciences, the CRISPR company co-founded by Jennifer Doudna, will stop developing its two off-the-shelf cell therapy programs for blood malignancies, citing a financing environment that CEO Rachel Haurwitz called increasingly challenging. The board has cleared management to evaluate a merger, acquisition or other transactions, with Wedbush Securities as exclusive financial advisor. Caribou ended the second quarter with $114 million in cash and securities, and Leerink analyst Daina Graybosch sees a reverse merger or a sale to Tang Capital as likely outcomes.

    Why it matters: A prominent CRISPR biotech with $114 million in cash is winding down and auctioning itself amid a wave of biotech reverse mergers.

Oct 8Thu
  1. biopharmadive.com65

    Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

    Caribou Biosciences, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, is discontinuing research, laying off staff and seeking strategic alternatives after failing to raise money to advance its allogeneic CAR-T programs. The move ends work on vispa-cel, which was ready for Phase 3 testing in lymphoma with an FDA-agreed trial design, and CB-011, in testing for multiple myeloma. The board will weigh mergers, acquisitions or other transactions, with the workforce reduction mostly done by year-end.

Oct 7Wed
  1. biospace.com67

    Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up

    Caribou Biosciences, co-founded by CRISPR pioneer Jennifer Doudna, will end all R&D activities, halt its clinical trials and make substantial staff cuts after failing to secure financing for its allogeneic CAR-T programs, including vispa-cel for B cell non-Hodgkin lymphoma and CB-011 for multiple myeloma. The company, which had $113.8 million in cash as of June 30 and expects $15 million to $19 million in restructuring costs, will explore a merger, acquisition or other strategic transactions.

    Why it matters: Collapse of a well-funded allogeneic CAR-T developer signals how far financing has frozen in that field.

  2. statnews.com62

    STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down

    Caribou Biosciences, the Berkeley, California CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, is shutting down after failing to raise the money needed for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma. CEO Rachel Haurwitz said the company had finalized the design of a Phase 3 trial for vispa-cel, its treatment for advanced B-cell non-Hodgkin lymphoma, with the FDA over the past year, but could not fund the study. Caribou will discontinue clinical development of both of its CRISPR-based CAR-T therapies.

Oct 2Fri
  1. biocentury.com44

    Trio of biotechs draw nine-figure fundings: Public Equity Report

    Immix Biopharma (NASDAQ:IMIX) raised $125 million in an offering underwritten by J.P. Morgan, announced minutes after an interim readout from the Phase II NEXICART-2 trial showed its BCMA-targeted CAR-T therapy NXC-201 achieved an 89% complete response rate among 45 patients with light-chain (AL) amyloidosis. Immix plans a BLA submission next year, when final data from the study are expected. Sagimet and Pyxis Oncology also raised nine-figure sums, alongside an AstraZeneca/Summit item.

Sep 10Thu
  1. biocentury.com45

    BrainChild: Bringing CAR Ts directly to the brain

    BrainChild Bio Inc. of Seattle and Cambridge, Mass., raised $116 million in series A financing backed by Seattle Children's Research Institute and WRF Capital, with an undisclosed family fund leading. The company delivers CAR T cells directly into the cerebrospinal fluid rather than the bloodstream, aiming to allow repeat dosing for CNS cancers while avoiding systemic toxicities seen in other CAR T programs. Targets include B7-H3, EGFR and IL-13RA2.

    Why it matters: New financing backs a repeat-dose intrathecal CAR T approach for CNS cancers.

Aug 24Mon
  1. fiercepharma.com42

    Cellares CEO seeks to 'resize' company after loss of 'large' cell therapy manufacturing customer

    Cellares co-founder and CEO Fabian Gerlinghaus said a "large pharmaceutical customer" has ended its partnership with the automated cell therapy manufacturer, requiring the South San Francisco company, which emerged in 2019, to "resize" through job cuts of unspecified scope. The unidentified customer's departure was "specific" to that company, and Cellares says the reduction will concentrate resources on clinical and commercial programs. Gerlinghaus says the customer base has more than doubled since the start of the year, following deals with Bristol Myers Squibb, Kite Pharma, Sonoma Biotherapeutics and a 10-year supply pact with Cabaletta Bio for rese-cel.

Aug 14Fri
  1. FiercePharma48

    It's BMS vs. Celgene investors once more after US appeals court revives lawsuit

    A U.S. appeals court in Manhattan has revived a lawsuit by Celgene shareholders who accuse Bristol Myers Squibb of deliberately slowing the FDA approval of Breyanzi to avoid paying more than $6 billion under a contingent value rights deal tied to its $74 billion acquisition of Celgene in 2019. The 3-0 ruling overturned Judge Jesse Furman's 2024 dismissal and found that trustee UMB Bank can maintain the suit because BMS accepted its appointment. A related breach-of-contract case was allowed to proceed in part in December, and it is uncertain how the decision affects it.

  2. FiercePharma40

    Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve

    Legend Biotech posted its first profitable quarter, with $63 million in adjusted net income for the three months ended June, as interim CEO Alan Bash discussed expanding Carvykti amid competition from Johnson & Johnson's bispecifics. Taiho and Cullinan Therapeutics' EGFR inhibitor zipalertinib plus chemotherapy succeeded in a phase 3 trial in first-line EGFR exon 20-mutated non-small cell lung cancer, with FDA approval plans ahead. A federal judge granted WuXi AppTec a preliminary injunction blocking the Defense Department's 1260H Chinese military company designation, and China approved Akeso's ivonescimab with chemotherapy for first-line squamous NSCLC.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org